Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs

Immunological Reviews

Volumn 203, Issue , 2005, Pages 127-142

  Pesu, Marko ^a   Candotti, Fabio ^b   Husa, Matthew ^a,c   Hofmann, Sigrun R ^a   Notarangelo, Luigi D ^d   O'Shea, John J ^a,e  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

^e NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYTOKINE RECEPTOR; IMATINIB; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE 3; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN TYROSINE KINASE;

ANIMAL MODEL; AUTOSOMAL RECESSIVE DISORDER; CLINICAL FEATURE; COMBINED IMMUNODEFICIENCY; GENE MUTATION; GENETIC ANALYSIS; JAK3 SEVERE COMBINED IMMUNODEFICIENCY; MOLECULAR MECHANICS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASE 3; MUTATION; PROTEIN-TYROSINE KINASES; RECEPTORS, CYTOKINE; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION;

EID: 13144260650     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00220.x     Document Type: Review

References (167)

1. Glanzmann E, Riniker P. Essentielle lymphocytophtose. Ein neues krankeitsbild aus der Sauglingspathologie. Ann Pediatr 1950;174:1-5.
2. Hitzig W, Bosch H, Huser HJ. Agammaglobulinemia & alymphocytosis with atrophy of lymphatic tissue. Helv Paediatr Acta 1958;13:551-585.
3. Buckley RH, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997;130:378-387.
4. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000;343:1313-1324.
5. Candotti F, Notarangelo L, Visconti R, O'Shea J. Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways. J Clin Invest 2002;109:1261-1269.
6. Notarangelo LD, et al. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma (c)-JAK3 signaling pathway as a model. Immunol Rev 2000;178:39-48.
7. Takeshita T, et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992;257:379-382.
8. Noguchi M, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993;73:147-157.
9. Puck JM, et al. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet 1993;2:1099-1104.
10. Markiewicz S, et al. Fine mapping of the human SCIDX1 locus at Xq12-13.1. Hum Mol Genet 1993;2:651-654.
11. Asao H, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001;167:1-5.
12. Leonard WJ, Noguchi M, Russell SM. Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID). Adv Exp Med Biol 1994;365:225-232.
13. Kondo M, et al. Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science 1994;263:1453-1454.
14. Kondo M, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 1993;262:1874-1877.
15. Kimura Y, et al. Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int Immunol 1995;7: 115-120.
16. Firmbach-Kraft I, Byers M, Shows T, Dalla-Favera R, Krolewski JJ. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene 1990;5:1329-1336.
17. Harpur AG, Andres AC, Ziemiecki A, Aston RR, Wilks AF. JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 1992;7:347-1353.
18. Krolewski JJ, Lee R, Eddy R, Shows TB, Dalla-Favera R. Identification and chromosomal mapping of new human tyrosine kinase genes. Oncogene 1990;5:277-282.
19. Wilks AF. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc Natl Acad Sci USA 1989;86:1603-1607.
20. Wilks AF. Cloning members of protein-tyrosine kinase family using polymerase chain reaction. Methods Enzymol 1991;200:533-546.
21. Wilks AF, Harpur AG, Kurban RR, Ralph SJ, Zurcher G, Ziemiecki A. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol 1991;11:2057-2065.
22. Kawamura M, et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci USA 1994;91:6374-6378.
23. Rane SG, Reddy EP. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994;9: 2415-2423.
24. Takahashi T, Shirasawa T. Molecular cloning of rat JAK3, a novel member of the JAK family of protein tyrosine kinases. FEBS Lett 1994;342:124-128.
25. Witthuhn BA, et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994;370:153-157.
26. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298:1912-1934.
27. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992;70:313-322.
28. Argetsinger LS, et al. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 1993;74:237-244.
29. Witthuhn BA, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993;74:227-236.
30. Muller M, et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 1993;366:129-135.
31. Silvennoinen O, Ihle JN, Schlessinger J, Levy DE. Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature 1993;366:583-585.
32. Silvennoinen O, Witthuhn BA, Quelle FW, Cleveland JL, Yi T, Ihle JN. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci USA 1993;90:8429-8433.
33. Watling D, et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 1993;366:166-170.
34. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-1421.
35. Rodig SJ, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93:373-383.
36. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93:397-409.
37. Parganas E, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-395.
38. Nosaka T, et al. Defective lymphoid development in mice lacking Jak3. Science 1995;270:800-802.
39. Park SY, et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995;3:771-782.
40. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995;270:794-797.
41. Shimoda K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000;13:561-571.
42. Karaghiosoff M, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000;13:549-560.
43. Boulay JL, O'Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 2003;19:159-163.
44. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322.
45. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109:S121-S131.
46. Johnston JA, et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 1995;92:8705-8709.
47. Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 2000;19:2566-2576.
48. Wurster AL, Tanaka T, Grusby MJ. The biology of Stat4 and Stat6. Oncogene 2000;19:2577-2584.
49. Johnston JA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994;370:151-153.
50. Boussiotis VA, et al. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science 1994;266:1039-1042.
51. Miyazaki T, et al. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994;266:1045-1047.
52. Russell SM, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 1994;266:1042-1045.
53. Macchi P, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377:65-68.
54. Russell SM, et al. Mutation of Jak3 in a patient with SCID. essential role of Jak3 in lymphoid development. Science 1995;270:797-800.
55. Candotti F, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 1997;90:3996-4003.
56. Bozzi F, et al. Molecular and biochemical characterization of JAK3 deficiency in a patient with severe combined immunodeficiency over 20 years after bone marrow transplantation: implications for treatment. Br J Haematol 1998;102:1363-1366.
57. Mella P, Schumacher RF, Cranston T, de Saint Basile G, Savoldi G, Notarangelo LD. Eleven novel JAK3 mutations in patients with severe combined immunodeficiency-including the first patients with mutations in the kinase domain. Hum Mutat 2001;18:355-356.
58. Notarangelo LD, et al. Mutations in severe combined immune deficiency (SCID) due to JAK3 deficiency. Hum Mutat 2001;18:255-263.
59. Roberts JL, et al. Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood 2004;103:2009-2018.
60. Baird AM, Lucas JA, Berg LJ. A profound deficiency in thymic progenitor cells in mice lacking Jak3. J Immunol 2000;165:3680-3688.
61. Thomis DC, Lee W, Berg LJ. T cells from Jak3-deficient mice have intact TCR signaling, but increased apoptosis. J Immunol 1997;159:4708-4719.
62. Cao X, et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995;2:223-238.
63. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci USA 1995;92:377-381.
64. Grossman WJ, et al. Dysregulated myelopoiesis in mice lacking Jak3. Blood 1999;94:932-939.
65. Vihinen M, et al. Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency. Clin Immunol 2000;96:108-118.
66. Chen M, et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol Cell Biol 2000;20:947-956.
67. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20:3387-3395.
68. Wan PT, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
69. Cacalano NA, et al. Autosomal SCID caused by a point mutation in the N-termimis of Jak3: mapping of the Jak3-receptor interaction domain. EMBO J 1999;18:1549-1558.
70. Chen M, et al. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci USA 1997;94:6910-6915.
71. Zhou YJ, et al. Unexpected effects of PERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell 2001;8:959-969.
72. Chen R, et al. Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nat Cell Biol 2001;3:439-444.
73. Cooper LA, Shen TL, Guan JL. Regulation of focal adhesion kinase by its amino-terminal domain through an autoinhibitory interaction. Mol Cell Biol 2003;23: 8030-8041.
74. Dunty JM, Gabarra-Niecko V, King ML, Ceccarelli DF, Eck MJ, Schaller MD. FERM domain interaction promotes FAK signaling. Mol Cell Biol 2004;24:5353-5368.
75. Radtke S, et al. Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression. J Biol Chem 2002;277:11297-11305.
76. Saharinen P, Silvennoinen O. The Janus kinase protein family. In: Sehgal PB, Levy DE, Hirano T, eds. Signal Transducers and Activators of Transcription (Stats) Activation and Biology. Dordrecht, the Netherlands: Kluwer Academic Publishers 2003:27-43.
77. Hofmann SR, et al. Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited. Mol Cell Biol 2004;24:5039-5049.
78. Shuai K, Liu B. Regulation of JAK-STAT signaling in the immune system. Nat Rev Immunol 2003;3:900-911.
79. Zhou YJ, et al. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc Natl Acad Sci USA 1997;94:13850-13855.
80. + T cell differentiation. Immunity 2003;18:475-487.
81. Sporri B, Kovanen PE, Sasaki A, Yoshimura A, Leonard WJ. JAB/SOCS1/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood 2001;97:221-226.
82. Cornish AL, et al. Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells. J Biol Chem 2003;278:22755-22761.
83. Ungureanu D, Saharinen P, Junttila I, Hilton DJ, Silvennoinen O. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol Cell Biol 2002;22:3316-3326.
84. Kamizono S, et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem 2001;276: 12530-12538.
85. Malakhova OA, et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev 2003;17:455-460.
86. Kurzer JH, Argetsinger LS, Zhou YJ, Kouadio JL, O'Shea JJ, Carter-Su C. Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Mol Cell Biol 2004;24:4557-4570.
87. O'Brien KB, O'Shea JJ, Carter-Su C. SH2-B family members differentially regulate JAK family tyrosine kinases. J Biol Chem 2002;277:8673-8681.
88. Asao H, et al. Hrs is associated with STAM, a signal-transducing adaptor molecule. Its suppressive effect on cytokine-induced cell growth. J Biol Chem 1997;272:32785-32791.
89. Takeshita T, et al. STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction. Immunity 1997;6:449-457.
90. Endo K, et al. STAM2, a new member of the STAM family, binding to the Janus kinases. FEBS Lett 2000;477:55-61.
91. Lohi O, Lehto VP. STAM/EAST/Hbp adapter proteins - integrators of signalling pathways. FEBS Lett 2001;508:287-290.
92. Lohi O, Poussu A, Mao Y, Quiocho F, Lehto VP. VHS domain - a longshoreman of vesicle lines. FEBS Lett 2002;513:19-23.
93. Musso T, et al. Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7. J Exp Med 1995;181:1425-1431.
94. Tortolani PJ, et al. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J Immunol 1995;155:5220-5226.
95. Aringer M, et al. Characterization and analysis of the proximal Janus kinase 3 promoter. J Immunol 2003;170:6057-6064.
96. Mangan JK, Rane SG, Kang AD, Amanullah A, Wong BC, Reddy EP. Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood 2004;103:4093-4101.
97. Fuel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998;20:394-397.
98. Kofoed EM, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003;349:1139-1147.
99. Roifman CM, Zhang J, Chitayat D, Sharfe N. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood 2000;96: 2803-2807.
100. Peschon JJ, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994;180:1955-1960.
101. Maki K, et al. Interleukin 7 receptor-deficient mice lack gammadelta T cells. Proc Natl Acad Sci USA 1996;93:7172-7177.
102. Candeias S, Peschon JJ, Muegge K, Durum SK. Defective T-cell receptor gamma gene rearrangement in interleukin-7 receptor knockout mice. Immunol Lett 1997;57:9-14.
103. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis?. Trends Immunol 2001;22:564-571.
104. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002;99:3892-3904.
105. Perumal NB, et al. TCR-gamma genes are rearranged but not transcribed in IL-7R alpha-deficient mice. J Immunol 1997;158:5744-5750.
106. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000;1:426-432.
107. Becker TC, et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 2002;195:1541-1548.
108. + T cells. J Exp Med 2002;195:1515-1522.
109. Seddon B, Tomlinson P, Zamoyska R. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol 2003;4:680-686.
110. Nutt SL, Urbanek P, Relink A, Busslinger M. Essential functions of Pax5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus. Genes Dev 1997;11:476-491.
111. Ozaki K, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002;298:1630-1634.
112. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004;22:625-655.
113. Cooper MA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002;100:3633-3638.
114. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002;13:169-183.
115. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991;352:621-624.
116. Kundig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I. Immune responses in interleukin-2-deficient mice. Science 1993;262:1059-1061.
117. Nelson BH. Interleukin-2 signaling and the maintenance of self-tolerance. Curr Dir Autoimmun 2002;5:92-112.
118. Refaeli Y, Van Parijs L, Abbas AK. Genetic models of abnormal apoptosis in lymphocytes. Immunol Rev 1999;169: 273-282.
119. Bassiri H, Carding SR. A requirement for IL-2/IL-2 receptor signaling in intrathymic negative selection. J Immunol 2001;166:5945-5954.
120. Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000;18:423-449.
121. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003;74:961-965.
122. Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc Natl Acad Sci USA 1997;94:3168-3171.
123. Roifman CM. Human IL-2 receptor alpha chain deficiency. Pediatr Res 2000;48:6-11.
124. Sharfe N, Shahar M, Roifman CM. An interleukin-2 receptor gamma chain mutation with normal thymus morphology. J Clin Invest 1997;100:3036-3043.
125. Frucht DM, et al. Unexpected and variable phenotypes in a family with JAK3 deficiency. Genes Immun 2001;2:422-432.
126. Mella P, et al. Development of autologous T lymphocytes in two males with X-linked severe combined immune deficiency: molecular and cellular characterization. Clin Immunol 2000;95:39-50.
127. Brugnoni D, et al. Development of autologous, oligoclonal, poorly functioning T lymphocytes in a patient with autosomal recessive severe combined immunodeficiency caused by defects of the Jak3 tyrosine kinase. Blood 1998;91:949-955.
128. Townsend JM, Fallon GP, Matthews JD, Smith P, Jolin EH, McKenzie NA. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000;13:573-583.
129. McMillan SJ, Bishop B, Townsend MJ, McKenzie AN, Lloyd CM. The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. J Exp Med 2002;195:51-57.
130. Carpino N, et al. Absence of an essential role for thymic stromal lymphopoietin receptor in murine B-cell development. Mol Cell Biol 2004;24:2584-2592.
131. + T-cell development. J Exp Med 2004;200:159-168.
132. + T cell homeostatic expansion. Nat Immunol 2004;5:426-434.
133. Villa A, et al. Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene. Blood 1996;88:817-823.
134. Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002;99:872-878.
135. Schumacher RF, et al. Complete genomic organization of the human JAK3 gene and mutation analysis in severe combined immunodeficiency by single-strand conformation polymorphism. Hum Genet 2000;106:73-79.
136. Hacia JG. Resequencing and mutational analysis using oligonucleotide microarrays. Nat Genet 1999;21:42-47.
137. Patel DD, Gooding ME, Parrott RE, Curtis KM, Haynes BF, Buckley RH. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 2000;342:1325-1332.
138. Antoine C, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 2003;361:553-560.
139. Haddad E, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 1998;91:3646-3653.
140. Wijnaendts L, Le Deist F, Griscelli C, Fischer A. Development of immunologic functions after bone marrow transplantation in 33 patients with severe combined immunodeficiency. Blood 1989;74:2212-2219.
141. Dror Y, et al. Immune reconstitution in severe combined immunodeficiency disease after lectin-treated, T-cell-depleted haplocompatible bone marrow transplantation. Blood 1993;81:2021-2030.
142. Laffort C, et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 2004;363:2051-2054.
143. Cavazzana-Calvo M, Hacein-Bey S, Yates F, de Villartay JP, Le Deist F, Fischer A. Gene therapy of severe combined immunodeficiencies. J Gene Med 2001;3:201-206.
144. Fischer A, Hacein-Bey S, Cavazzana-Calvo M. Gene therapy of severe combined immunodeficiencies. Nat Rev Immunol 2002;2:615-621.
145. Candotti F, Johnston JA, Puck JM, Sugamura K, O'Shea JJ, Blaese RM. Retroviral-mediated gene correction for X-linked severe combined immunodeficiency. Blood 1996;87:3097-3102.
146. Candotti F, Oakes SA, Johnston JA, Notarangelo LD, O'Shea JJ, Blaese RM. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J Exp Med 1996;183:2687-2692.
147. Candotti F, O'Shea JJ, Villa A. Severe combined immune deficiencies due to defects of the common gamma chain-JAK3 signaling pathway. Springer Semin Immunopathol 1998;19:401-415.
148. Oakes SA, et al. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity 1996;5:605-615.
149. Otsu M, Anderson SM, Bodine DM, Puck JM, O'Shea JJ, Candotti F. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy. Mol Ther 2000;1:145-153.
150. Hacein-Bey H, et al. gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. Blood 1996;87:3108-3116.
151. Hacein-Bey S, Basile GD, Lemerle J, Fischer A, Cavazzana-Calvo M. gammac gene transfer in the presence of stem cell factor, FLT-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from gammac (-) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures. Blood 1998;92:4090-4097.
152. Bunting KD, Sangster MY, Ihle JN, Sorrentino BP. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med 1998;4:58-64.
153. Bunting KD, Flynn KJ, Riberdy JM, Doherty PC, Sorrentino BP. Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency. Proc Natl Acad Sci USA 1999;96:232-237.
154. Bunting KD, Lu T, Kelly PF, Sorrentino BP. Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation. Hum Gene Ther 2000;11:2353-2364.
155. Hacein-Bey-Abina S, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-1193.
156. + cells. Mol Ther 2003;7:5449.
157. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994;78:45-57.
158. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA 1998;95:3890-3895.
159. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci USA 1991;88:4367-4371.
160. Neale GA, Rehg JE, Goorha RM. Disruption of T-cell differentiation precedes T-cell tumor formation in LMO-2 (rhombotin-2) transgenic mice. Leukemia 1997;11:289-290.
161. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002;1:31-36.
162. Thompson JE, et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 2002;12:1219-1223.
163. Meydan N, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996;379:645-648.
164. Kirken RA, et al. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol 1999;65:891-899.
165. Changelian PS, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-878.
166. Sudbeck EA, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999;5:1569-1582.
167. Saemann MD, et al. Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154. Transplantation 2003;75:1864-1872.